Drug Profile


Alternative Names: ALXN 1210

Latest Information Update: 05 Jul 2017

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Phase I Immunological disorders

Most Recent Events

  • 13 Apr 2017 Phase-III clinical trials in Paroxysmal nocturnal haemoglobinuria (Treatment-experienced) in Canada, France, Japan, Germany, Spain (IV) (EudraCT2016-002026-36; NCT03056040)
  • 21 Feb 2017 Alexion plans a phase III trial for Paroxysmal nocturnal haemoglobinuria (NCT03056040)
  • 16 Feb 2017 Alexion Pharmaceuticals completes enrolment in a phase I/II trial in Paroxysmal nocturnal haemoglobinuria (Treatment-naive) in Australia and South Korea before February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top